Rivaroxaban in cervical and "cervico-cerebral" artery dissections: a new therapeutic option?
Cervical and cervico-cerebral artery dissections
DOACs
Neurosonology
Rivaroxaban
Stroke
Transcranial color Doppler
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
21
12
2018
accepted:
02
04
2019
pubmed:
14
4
2019
medline:
14
1
2020
entrez:
14
4
2019
Statut:
ppublish
Résumé
Antiplatelet agents and vitamin K antagonists (VKA) are usually used in the treatment of cervical (carotid or vertebral) artery dissections (CADs); however, data about the use of direct oral anticoagulants (DOACs) in these conditions are very limited. DOACs have proven to be effective in stroke reduction in non-valvular atrial fibrillation and, when possible, they are preferred to warfarin because of their better safety profile. We describe four cases of CADs and, firstly in literature, cervico-cerebral (CCADs) in young patients (average age of 42 years) treated with rivaroxaban 20 mg daily. Three of these four dissections had affected the vertebral artery (condition with an unfavorable prognosis and more often complicated by subarachnoid hemorrhages), and the other one was a carotid dissection at the extra-intracranial passage. All patients were followed clinically and with serial neurosonological examinations at 1, 3, and 6 months and with magnetic resonance angiography (MRA) at 6 months. All patients presented a good outcome with vascular recanalization without stroke recurrence or bleedings, even in patients with intracranial vertebral artery involvement. DOACs could be an alternative in young patients with CADs and their use could be considered in intracranial artery dissections too.
Identifiants
pubmed: 30980197
doi: 10.1007/s10072-019-03882-8
pii: 10.1007/s10072-019-03882-8
doi:
Substances chimiques
Factor Xa Inhibitors
0
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1591-1596Références
N Engl J Med. 2001 Mar 22;344(12):898-906
pubmed: 11259724
Stroke. 2004 Feb;35(2):482-5
pubmed: 14757894
Eur Radiol. 2007 Apr;17(4):983-93
pubmed: 16670864
Front Neurol Neurosci. 2005;20:12-15
pubmed: 17290107
Clin Hemorheol Microcirc. 2007;36(2):141-53
pubmed: 17325438
Stroke. 2007 Sep;38(9):2605-11
pubmed: 17656656
Cerebrovasc Dis. 2008;25(5):457-507
pubmed: 18477843
J Clin Ultrasound. 2008 Oct;36(8):472-9
pubmed: 18626872
Neurol Res. 2008 Sep;30(7):687-9
pubmed: 18826800
J Clin Neurosci. 2009 Jan;16(1):79-82
pubmed: 19017557
J Korean Neurosurg Soc. 2008 Sep;44(3):109-15
pubmed: 19096659
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Stroke. 2010 Apr;41(4):717-21
pubmed: 20150549
Cochrane Database Syst Rev. 2010 Oct 06;(10):CD000255
pubmed: 20927720
Stroke. 2011 Aug;42(8):e420-63
pubmed: 21282494
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Neurologist. 2012 Sep;18(5):255-60
pubmed: 22931729
Pharmacol Res. 2013 Aug;74:49-55
pubmed: 23714416
Cerebrovasc Dis. 2014;38(4):247-53
pubmed: 25401389
Lancet Neurol. 2015 Apr;14(4):361-7
pubmed: 25684164
Brain Behav. 2015 Aug;5(8):e00349
pubmed: 26356074
J Neurol Sci. 2015 Nov 15;358(1-2):371-6
pubmed: 26434614
Neurosurgery. 2017 Mar 1;80(3):368-379
pubmed: 28362967
Int J Cardiol. 2017 Oct 1;244:282-284
pubmed: 28629627
J Stroke Cerebrovasc Dis. 2018 Feb;27(2):438-444
pubmed: 29100856
J Neuroimaging. 2018 Jul;28(4):350-358
pubmed: 29727515